FOR IMMEDIATE RELEASE DATE: March 25, 2025 Contact: Lisa Owens, 210-601-6647 With continued global expansion plans, NEXT Oncology is one of the largest Phase 1 Cancer Trial organizations in the world. (SAN ANTONIO, TX) March 25, 2025 ––NEXT Oncology has opened its seventh cancer care center in Houston, Texas as part of the company’s global growth initiative. NEXT – Houston, …
NEXT Oncology Moves Cancer Research Forward
NEXT Oncology, a Phase 1 Clinical Trial organization with six locations around the world, played a significant role in moving cancer research forward at the recent American Society of Clinical Oncology (ASCO) meeting in Chicago. Clinical investigators from NEXT locations around the world presented 25 abstracts, posters and presentations on the status of ongoing Phase 1 clinical trials at NEXT …
NEXT Oncology and OncoBay Clinical Collaborate on Six Phase 1 Clinical Trials
FOR IMMEDIATE RELEASE DATE: April 22, 2024 Contact: Lisa Owens, 210-601-6647 (SAN ANTONIO, TX and RALEIGH, NC) April 22, 2024 ––NEXT Oncology, a Phase 1 Clinical Trial organization with six locations around the world, and OncoBay Clinical, a leading oncology-focused full-service CRO, are collaborating on six Phase 1 Clinical trials in 10 study site locations globally to advance OncoBay’s innovative …
Announcing the 2024 Health Care Heroes
“We are so proud of our founder and CEO, Dr. Anthony Tolcher” for being named one of San Antonio’s Health Care Heroes by the San Antonio Business Journal. We will celebrate his achievements on May 22, 2024. Read more here.
NEXT Oncology is the perfect place to compassionately improve outcomes for patients with cancer, now and in the future.
“Cancer has no geographic boundaries,” said Dr. Tolcher, CEO and founder of NEXT Oncology. “One of the continuing challenges has been that cancer research has been conducted in silos. Our goal has always been to break down those barriers and bring potentially life-saving therapies to people in other cities within Texas, while at the same time expediting the development of new …
Update on Conservative Management of the Axilla when the Sentinel Node is Positive in Breast cancer.
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. Recently, there was an update on the AMAROS trial that now has 10-year results. In order to have perspective on this report, it is important to know that …
Oserdu FDA approval for Recurrent Metastatic Hormone Receptor Positive Breast cancer with ESR1 mutations
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. Oserdu, an Oral SERD, was recently FDA approved for Recurrent Metastatic Hormone Receptor Positive Breast cancer with ESR1 mutations. What does this mean for women with breast cancer? …
Primary Results from the Randomized PHASE II RIGHT Choice Trial of Premenopausal Patients with Aggressive HR+/HER 2 Neu- Advanced Brest Cancer Treated with Ribociclib Endocrine Therapy versus Treatment of Physicians Choice Combination Chemotherapy.
Presented at SABCS 2022 by Len-Shu Lu from the National Taiwan University Hospital, Taipei Taiwan. Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. The use of CDK4/6 inhibitors has emerged as a valuable treatment in the …
Evaluation of the Breast Cancer Index in Premenopausal women with Early Stage HR+ Breast Cancer in the Soft Trial.
Presented by Ruth O’ Regan et al. Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. This was a review of the tool called the Breast Cancer Index and its application for predicting the benefit of the …
ADCs in Breast Oncology: Present & Future
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. Educational Symposium on ADCs @ December 2022 SABCS. Bioengineering & Mechanism of Action of Antibody Drug Conjugates (ADC) Presentation from Puja Sapra, PhD with SVP Biologics Engineering and …